Overview Dividends

(NTRA) Natera - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6323071042

Prenatal Screening, Carrier Screening, Cancer Monitoring, Transplant Assessment, Genetic Profiling

EPS (Earnings per Share)

EPS (Earnings per Share) of NTRA over the last years for every Quarter: "2020-09": -0.72, "2020-12": -0.92, "2021-03": -0.74, "2021-06": -1.32, "2021-09": -1.63, "2021-12": -1.48, "2022-03": -1.45, "2022-06": -1.5, "2022-09": -1.25, "2022-12": -1.37, "2023-03": -1.23, "2023-06": -0.97, "2023-09": -0.95, "2023-12": -0.64, "2024-03": -0.56, "2024-06": -0.3, "2024-09": -0.26, "2024-12": -0.41, "2025-03": -0.5, "2025-06": -0.74, "2025-09": -0.64,
EPS Growth (3y CAGR): 149.85%
EPS Trend (3y Corr): 68.4%
Last SUE: -1.52σ
Qual. Beats: 0

Revenue

Revenue of NTRA over the last years for every Quarter: 2020-09: 98.143, 2020-12: 112.378, 2021-03: 152.316, 2021-06: 142.026, 2021-09: 158.116, 2021-12: 173.028, 2022-03: 194.133, 2022-06: 198.2, 2022-09: 210.637, 2022-12: 217.252, 2023-03: 241.756, 2023-06: 261.404, 2023-09: 268.306, 2023-12: 311.105, 2024-03: 367.741, 2024-06: 413.351, 2024-09: 439.758, 2024-12: 476.061, 2025-03: 501.83, 2025-06: 546.6, 2025-09: 592.183,
Revenue Growth (3y CAGR): 44.00%
Revenue Trend (3y Corr): 99.3%
Last SUE: 3.26σ
Qual. Beats: 11
Risk via 10d forecast
Volatility 44.4%
Value at Risk 5%th 67.7%
Relative Tail Risk -7.22%
Reward TTM
Sharpe Ratio 0.85
Alpha 12.80
Character TTM
Hurst Exponent 0.649
Beta 1.276
Beta Downside 1.181
Drawdowns 3y
Max DD 39.94%
Mean DD 8.29%
Median DD 5.94%

Description: NTRA Natera October 16, 2025

Natera (NTRA) is a global molecular diagnostics firm that leverages next-generation sequencing to offer a portfolio of non-invasive prenatal tests (Panorama, Vistara, Horizon), hereditary cancer and carrier-screening assays (Empower, Anora), and specialty oncology and transplant monitoring tools (Signatera, Altera, Prospera, Renasight). The company also provides the cloud-based analytics platform Constellation and distributes its products through a mix of direct sales, laboratory partners, and collaborations with BGI Genomics and Foundation Medicine.

In FY 2024 Natera reported $1.03 billion in revenue, reflecting a 28 % year-over-year increase driven primarily by strong growth in its prenatal and oncology segments. The firm’s gross margin expanded to 78 % as it scaled its high-margin NIPT assays, while its cash-flow conversion improved to $180 million, underscoring the capital-efficient nature of its SaaS-enabled test platform. Key sector drivers include rising global demand for non-invasive prenatal screening-projected to exceed $5 billion by 2028-and expanding reimbursement for liquid-biopsy oncology tests, which together create a tailwind for Natera’s recurring-revenue model.

If you’re looking to deepen your valuation analysis, a quick review of ValueRay’s quantitative models for NTRA can surface hidden upside and risk factors worth exploring further.

NTRA Stock Overview

Market Cap in USD 27,695m
Sub-Industry Biotechnology
IPO / Inception 2015-07-02
Return 12m vs S&P 500 17.2%
Analyst Rating 4.48 of 5

NTRA Dividends

Currently no dividends paid

NTRA Growth Ratios

Metric Value
CAGR 3y 81.06%
CAGR/Max DD Calmar Ratio 2.03
CAGR/Mean DD Pain Ratio 9.78
Current Volume 1076.3k
Average Volume 1289.1k

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-309.2m TTM) > 0 and > 6% of Revenue (6% = 127.0m TTM)
FCFTA 0.06 (>2.0%) and ΔFCFTA 7.91pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 47.49% (prev 66.66%; Δ -19.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.11 (>3.0%) and CFO 194.3m > Net Income -309.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (137.2m) change vs 12m ago 10.84% (target <= -2.0% for YES)
Gross Margin 63.70% (prev 57.66%; Δ 6.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 124.1% (prev 96.29%; Δ 27.76pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -69.90 (EBITDA TTM -268.8m / Interest Expense TTM 4.37m) >= 6 (WARN >= 3)

Altman Z'' -7.84

(A) 0.55 = (Total Current Assets 1.45b - Total Current Liabilities 442.0m) / Total Assets 1.82b
(B) -1.55 = Retained Earnings (Balance) -2.82b / Total Assets 1.82b
warn (B) unusual magnitude: -1.55 — check mapping/units
(C) -0.18 = EBIT TTM -305.5m / Avg Total Assets 1.71b
(D) -4.96 = Book Value of Equity -2.82b / Total Liabilities 569.3m
Total Rating: -7.84 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 47.29

1. Piotroski 4.50pt = -0.50
2. FCF Yield 0.40% = 0.20
3. FCF Margin 5.01% = 1.25
4. Debt/Equity 0.15 = 2.49
5. Debt/Ebitda 3.19 = -2.01
6. ROIC - WACC (= -33.96)% = -12.50
7. RoE -25.07% = -2.50
8. Rev. Trend 99.26% = 7.44
9. EPS Trend 68.37% = 3.42

What is the price of NTRA shares?

As of November 19, 2025, the stock is trading at USD 206.04 with a total of 1,076,259 shares traded.
Over the past week, the price has changed by -0.29%, over one month by +13.40%, over three months by +27.86% and over the past year by +34.30%.

Is NTRA a buy, sell or hold?

Natera has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NTRA.
  • Strong Buy: 12
  • Buy: 8
  • Hold: 0
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the NTRA price?

Issuer Target Up/Down from current
Wallstreet Target Price 227.9 10.6%
Analysts Target Price 227.9 10.6%
ValueRay Target Price 269.4 30.8%

NTRA Fundamental Data Overview November 15, 2025

Market Cap USD = 27.70b (27.70b USD * 1.0 USD.USD)
P/S = 13.0844
P/B = 22.1176
Beta = 1.643
Revenue TTM = 2.12b USD
EBIT TTM = -305.5m USD
EBITDA TTM = -268.8m USD
Long Term Debt = 118.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 80.3m USD (from shortTermDebt, last quarter)
Debt = 184.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -856.7m USD (from netDebt column, last quarter)
Enterprise Value = 26.84b USD (27.70b + Debt 184.7m - CCE 1.04b)
Interest Coverage Ratio = -69.90 (Ebit TTM -305.5m / Interest Expense TTM 4.37m)
FCF Yield = 0.40% (FCF TTM 106.1m / Enterprise Value 26.84b)
FCF Margin = 5.01% (FCF TTM 106.1m / Revenue TTM 2.12b)
Net Margin = -14.61% (Net Income TTM -309.2m / Revenue TTM 2.12b)
Gross Margin = 63.70% ((Revenue TTM 2.12b - Cost of Revenue TTM 768.4m) / Revenue TTM)
Gross Margin QoQ = 64.91% (prev 63.50%)
Tobins Q-Ratio = 14.73 (Enterprise Value 26.84b / Total Assets 1.82b)
Interest Expense / Debt = 0.57% (Interest Expense 1.04m / Debt 184.7m)
Taxrate = -0.24% (negative due to tax credits) (207.0k / -87.3m)
NOPAT = -306.2m (EBIT -305.5m * (1 - -0.24%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.27 (Total Current Assets 1.45b / Total Current Liabilities 442.0m)
Debt / Equity = 0.15 (Debt 184.7m / totalStockholderEquity, last quarter 1.25b)
Debt / EBITDA = 3.19 (negative EBITDA) (Net Debt -856.7m / EBITDA -268.8m)
Debt / FCF = -8.08 (Net Debt -856.7m / FCF TTM 106.1m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.97% (Net Income -309.2m / Total Assets 1.82b)
RoE = -25.07% (Net Income TTM -309.2m / Total Stockholder Equity 1.23b)
RoCE = -22.60% (EBIT -305.5m / Capital Employed (Equity 1.23b + L.T.Debt 118.4m))
RoIC = -23.31% (negative operating profit) (NOPAT -306.2m / Invested Capital 1.31b)
WACC = 10.65% (E(27.70b)/V(27.88b) * Re(10.72%) + D(184.7m)/V(27.88b) * Rd(0.57%) * (1-Tc(-0.00)))
Discount Rate = 10.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.23%
[DCF Debug] Terminal Value 59.43% ; FCFE base≈106.1m ; Y1≈69.6m ; Y5≈31.8m
Fair Price DCF = 3.11 (DCF Value 429.7m / Shares Outstanding 138.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 68.37 | EPS CAGR: 149.9% | SUE: -1.52 | # QB: 0
Revenue Correlation: 99.26 | Revenue CAGR: 44.00% | SUE: 3.26 | # QB: 11

Additional Sources for NTRA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle